Similar to EGFR, the KRAS status may also be discordant between primary and metastatic tissues (44) and a KRAS mutation in a small subset of tumor cells may confer resistance to EGFR tyrosine kinase inhibitors (TKIs) therapy. Here, KRAS is linked to neoplasm.